

1 **Sputum microbiota profiles of treatment-naïve TB**  
2 **patients in Uganda before and during first-line**  
3 **therapy**  
4

5 David Patrick Kateete<sup>1§</sup>, Monica M Mbabazi<sup>1</sup>, Faith Nakazzi<sup>1</sup>, Fred A  
6 Katabazi<sup>1</sup>, Edgar Kigozi<sup>1</sup>, Willy Ssengooba<sup>2</sup>, Lydia Nakiyingi<sup>3,4</sup>, Sharon  
7 Namiiro<sup>5</sup>, Alphonse Okwera<sup>5</sup>, Moses L Joloba<sup>1</sup> and Adrian Muwonge<sup>6§</sup>

8  
9 <sup>1</sup>Department of Immunology & Molecular Biology, School of Biomedical Sciences,  
10 Makerere University College of Health Sciences, Kampala, Uganda

11 <sup>2</sup>BSL-3 Mycobacteriology Laboratory, Department of Medical Microbiology, School of  
12 Biomedical Sciences, Makerere University College of Health Sciences, Kampala,  
13 Uganda

14 <sup>3</sup>Department of Medicine, School of Medicine, Makerere University College of Health  
15 Sciences, Kampala, Uganda

16 <sup>4</sup>Infectious Diseases Institute, Makerere University College of Health Sciences,  
17 Mulago Hospital Complex, Kampala, Uganda

18 <sup>5</sup>TB Clinics, Mulago National Referral Hospital, Kampala, Uganda

19 <sup>6</sup>Division of Genetics and Genomics, Division of Infection and Immunity, The Roslin  
20 institute, University of Edinburgh, Edinburgh, UK

21 <sup>§</sup>Contributed equally

22 Correspondence to [dkateete@chs.mak.ac.ug](mailto:dkateete@chs.mak.ac.ug) & [adrian.muwonge@roslin.ed.ac.uk](mailto:adrian.muwonge@roslin.ed.ac.uk)

## 23 **Abstract**

24 There is limited information on microbiota dynamics in tuberculosis (TB) in Africa. Here, we  
25 investigated changes in microbiota composition, abundance, co-occurrence and community  
26 remodelling relative to clinical parameters, among treatment-naïve pulmonary TB patients at  
27 Mulago National Referral Hospital in Kampala, Uganda. We sequenced 205 sputum  
28 samples from 120 patients before initiating anti-TB therapy (baseline) and during treatment  
29 follow-up (at months 2 and 5). A total of 8.6 million high quality sequences were generated,  
30 yielding 8,180 operational taxonomic units (OTUs), 18 phyla and 333 genera. A sputum  
31 sample on average generated 44,992 sequences, yielding 6,580 OTUs, 4 phyla and 36  
32 genera. The sputum microbiota core comprised of 34 genera and it was remarkably stable  
33 during treatment. Month 2 was characterized by a significant mean reduction in core  
34 microbiota biomass, limited variance changes and general lack of entropy. However,  
35 variance and entropy recovered at month 5. Co-occurrence patterns were predominated by  
36 accessory genera at baseline but their abundance significantly reduced during treatment.  
37 Our findings reveal discernible sputum microbiota signals associated with first-line anti-TB  
38 therapy, with potential to inform treatment response monitoring in developing countries.

## 39 Introduction

40 Tuberculosis (TB) is a persistent public health problem and one of the top 10 causes of  
41 death worldwide<sup>1</sup>. Nearly half a million new TB cases have been reported in Uganda since  
42 2010<sup>2</sup>, and the TB incidence in the country surpassed that of HIV-infection in 2016<sup>3</sup>. While  
43 the introduction of the Xpert MTB/RIF assay revolutionized the diagnosis of TB globally<sup>4</sup>,  
44 treatment still hinges on long treatment regimens i.e. 6 to 24 months depending on whether  
45 treating drug susceptible TB or drug resistant TB<sup>5</sup>. The standard first-line treatment regimen  
46 comprises of an intensive phase of 2 months treatment with isoniazid, rifampicin,  
47 pyrazinamide and ethambutol, followed by a continuation phase of 4 months treatment with  
48 isoniazid and rifampicin<sup>6,7</sup>. After initiating therapy, sputum microscopy for identification of  
49 mycobacteria (in form of acid-fast bacilli, AFB) or sputum culturing for *Mycobacterium*  
50 *tuberculosis* growth, are regularly done during the treatment period usually at months 2 and  
51 5 to monitor treatment response. Attaining sputum sterilisation, also known as sputum  
52 smear-conversion or sputum culture-conversion (i.e. from AFB/culture positive to  
53 AFB/culture negative) at months 2 or 5 after initiating therapy is a known cardinal index of  
54 treatment success. In fact, the World Health Organization (WHO) guidelines state that “a  
55 patient whose sputum was AFB smear-positive or culture-positive at the beginning of  
56 therapy but becomes smear-negative or culture-negative in the last month of treatment and  
57 on at least one previous occasion is declared cured”<sup>6,8</sup>. Despite the importance of sputum-  
58 smear / sputum-culture conversion in monitoring treatment response<sup>9</sup>, they have low  
59 sensitivity and in low-income countries culture is not routinely done. However, as sputum is  
60 the cornerstone in diagnosing TB, holistic identification of microbiological factors in sputum  
61 and their association with treatment response could unravel new ways in which TB diagnosis  
62 or treatment response monitoring can be improved<sup>7</sup>.

63

64 Microbiota are ‘microorganisms’ –bacteria, fungi, protozoa and viruses that live on the skin  
65 and mucosa of humans and other mammals. Their role in induction, maintaining, disrupting

66 and modulation of the immune response has recently come into focus with the advent of the  
67 human microbiome project<sup>10</sup>. Microbiota also exist in the lung<sup>11</sup>, the predilection site for the  
68 TB causative agent *M. tuberculosis*, and perhaps influence its behaviour in a variety of ways  
69 e.g. signalling<sup>11-13</sup>. Therefore, sound understanding of the microbiota in TB is necessary  
70 given their emerging importance in human and animal health<sup>11,14</sup>. In this context, microbiota  
71 profiling in pulmonary TB can advance our knowledge of TB pathogenesis and unravel new  
72 ways in which TB diagnostics might be improved<sup>7,11-13</sup>. While microbiota/microbiome studies  
73 in TB have advanced<sup>11,12,15,16</sup>, there is a general lack of knowledge in sub-Saharan Africa<sup>11</sup>  
74 where the TB burden is greatest. The aim of this study was to investigate the microbiota  
75 profiles among treatment-naïve TB in Kampala, Uganda, and the impact of first-line anti-TB  
76 therapy on the microbiota, using sputum as proxy for the lung environment<sup>17</sup>. We describe  
77 sputum microbiota changes during critical transitions of anti-TB therapy: Pre-treatment  
78 (baseline) and treatment response follow-up at months 2 and 5.

79

## 80 Results and Discussion

### 81 Demographics

82 This study enrolled 120 treatment-naïve pulmonary TB patients at Mulago National Referral  
83 Hospital in Kampala Uganda, in the period between 2016 and 2018. Two hundred and five  
84 sputum samples were collected from the patients and sequenced –120 at baseline, 44 at  
85 month 2, and 41 at month 5 (**Figure 1**). **Table 1** summarises the clinical and demographic  
86 characteristics of the patients. The mean age was 33 years; majority were male, residents of  
87 Kampala and Wakiso districts (**Supplementary Figure S1** online).

88

89 **Table 1:**

90 **Clinical and demographic characteristics of pulmonary TB patients enrolled (n=120)**

Variable	Patients (%)	Proportion by gender (%)	
		Female	Male
<b>HIV status</b>			
Positive	26 (21.7)	12 (46.2)	14 (53.8)
Negative	94 (78.3)	32 (34)	62 (66)
<b>Chest X-ray</b>			

Cavities	66	25	41
No cavities	37	10	27
<b>Medication</b>			
HIV-positive on ART	16 (60)	8 (0.5)	8 (0.5)
History of antibiotic use	22 (18.3)	8 (36.4)	14 (63.6)
Others*	23 (19.2)	11 (47.8)	12 (52.2)
<b>Comorbidity</b>			
High blood pressure / hypertension	10 (8.3)	2 (20)	8 (80)
Cigarette smokers	26 (21.7)	1 (3.8)	25 (96.2)
Alcohol consumers	40 (33.5)	11 (27.5)	29 (72.5)
<b>BMI</b>			
Low ( $\leq 18$ )	64 (53.3)	21 (32.8)	43 (67.2)
Medium ( $\geq 19-25$ )	52 (43.4)	19 (36.5)	33 (63.5)
High ( $\geq 26-29$ )	4 (3.3)	4 (100)	0
<b>Education</b>			
Illiterate	7 (5.8)	4 (57.1)	3 (42.9)
Primary level	27 (22.5)	12 (44.4)	15 (55.6)
Secondary level (O-levels)	86 (71.7)	29 (33.7)	57 (66.3)
<b>District of residence</b>			
Kampala	63 (52.5)	26 (41.3)	37 (58.7)
Wakiso	40 (33.3)	14 (35)	26 (65)
Others**	17 (14.2)	4 (23.5)	13 (76.5)
<b>Ancestry</b>			
Bantu	100 (83.3)	37 (37)	63 (67)
Non-Bantu	20 (16.7)	7 (35)	13 (65)
<b>Employment status</b>			
Employed	97 (80.8)	34 (35.1)	63 (64.9)
Not employed	23 (19.2)	10 (43.5)	13 (56.5)
<b>CFM</b>			
No AFB	19 (15.8)	9 (47.4)	10 (52.6)
Scanty	20 (16.7)	6 (30)	14 (70)
1+ AFB	12 (10)	4 (33.3)	8 (66.7)
2+ AFB	30 (25)	12 (40)	18 (60)
3+ AFB	39 (32.5)	13 (33.3)	26 (66.7)
<b>Sampling point</b>			
Baseline (before treatment)	120 (100)	53 (44.2)	67 (55.8)
1 <sup>st</sup> treatment follow up (2 months after)	44 (36.7)	15 (34.1)	29 (65.9)
2 <sup>nd</sup> treatment follow up (5 months after)	41 (34.2)	16 (39)	25 (61)

- 91
- 92
- 93
- 94
- 95
- \*Refers to medicines other than antibiotics & antiretroviral (ARVs)
  - \*\*Refers to participants staying in districts other than Kampala & Wakiso. Difference in sums was due to sequences removed during filtering.
  - ART, antiretroviral therapy; AFB, acid fast bacilli; BMI, body mass index; CFM, conventional fluorescence microscopy; COPD, chronic obstructive pulmonary disease

96

### 97 Sputum microbiota structure of treatment-naïve TB patients

98 High-throughput sequencing of the variable region of the *16S rRNA* gene generated a total

99 of 9,316,821 sequence reads from the 205 sputum samples. After filtering and quality

100 control, we retained 8,638,640 sequences representing 192 samples i.e. 13 samples were

101 removed due to low sequence quality. The retained high quality sequences yielded 8,180  
102 OTUs, 18 phyla and 333 genera. A sputum sample on average generated 44,992  
103 sequences, yielding 6,580 OTUs, 4 phyla and 36 genera. Six hundred and seventeen OTUs  
104 and 91 genera were shared between patients across the sampling points i.e. baseline,  
105 months 2 and 5 (**Supplementary Figure S2** online). Bacteroidetes, Firmicutes,  
106 Proteobacteria, Fusobacteria and Actinobacteria were the most predominant phyla  
107 accounting for nearly 95% of the sputum microbiota composition. We observed that negative  
108 sputum samples on Löwenstein-Jensen (LJ) culturing produced more sequence reads  
109 (**Supplementary files Table S1 and Figure S3** online) however, the *Mycobacterium*  
110 sequences detected matched the expected outcomes with routine TB diagnostic methods  
111 i.e. positive likelihood ratio of 0.71 (95% CI=0.59, 0.85). While sputum microbiota of  
112 pulmonary TB patients has been investigated before and researchers provided key insight  
113 into its composition and diversity, majority of the studies were conducted in Asia<sup>11,16,18,19</sup>. Our  
114 study generated nearly 16 times the number of OTUs reported by investigators in Asia<sup>15,16</sup>,  
115 probably because of the latest amplicon sequencing technology we used (i.e. MiSeq/Illumina  
116 Inc. vs. 456/Pyrosequencing in previous studies). Conversely, these differences may signify  
117 existence of high sputum microbiota diversity among TB patients in Uganda: Indeed, the  
118 microbiota diversity observed in this study accounts for nearly 48% of the diversity in the  
119 human oral microbiome database <http://www.homd.org>.

120

### 121 ***Alpha and beta diversity***

122 On average, a sputum sample from a treatment-naïve TB patient had a Shannon diversity  
123 index of 3.8 and this was not affected by HIV status, contradicting some reports from  
124 Asia<sup>16,20</sup>. Generally we observed no difference with respect to sampling points (i.e. baseline,  
125 months 2 & 5) at alpha diversity level on indices like richness, Simpson and Shannon  
126 (**Figure 2, panel A**). However for beta diversity, we observed distinct clustering of patients  
127 when we analysed treatment follow-up samples relative to baseline samples (before  
128 initiating therapy) **Fig.2 (panel B)** suggesting occurrence of sputum microbial signals during

129 treatment that could be exploited for insight into improving treatment response monitoring.  
130 Clinical and lifestyle variables in this study explained approx. 14% of the microbial variance.  
131 Most of this variance was attributed to treatment follow up samples (months 2 & 5), which  
132 again highlights the potential utility of sputum microbiota in monitoring treatment response<sup>21</sup>.  
133 It is noteworthy that the total explained variance observed was similar to that estimated in  
134 PERMANOVA (permutational multivariate analysis of variance, see Methods). The  
135 relationship between effect-sizes of clinical variables and Bray-Curtis changes, weighted and  
136 unweighted uniFrac distances is shown in **Supplementary files Fig.S4** and **Table S3** online  
137 (i.e. colony forming units, 1.6%, 1.6%, 1.1%; body mass index, 1.1%, 1.0%, 0.8%; sampling  
138 point, 1.4%, 2.3%, 2.0%; nutritional status, 0.6%, 0.5%, 0.7%; and smoking, 0.5%, 0.7%,  
139 2.7%). In this PERMANOVA analysis these variables cumulatively explained 11-14% of the  
140 variance across beta diversity indices. Since the largest proportion of explained variance  
141 was attributed to sampling point and sputum smear staining (**Fig.2 panel B**), it is likely that  
142 additional sputum microbial factors that change with treatment do occur.

143

#### 144 **Taxonomy characteristics during treatment: Accessory microbiota fluctuates while** 145 **core microbiota is stable**

146 To unravel the effect of anti-TB treatment on the microbiota, we characterised and tracked  
147 the size and composition of the 'core' and 'accessory' microbiota in sputum samples  
148 collected during treatment follow-up relative to baseline samples (**Figures 3-5**). By 'core  
149 microbiota' we refer to genera present in eighty percent of samples at a given sampling  
150 point<sup>22</sup>, in this case baseline, months 2 and 5; 'accessory microbiota' refers to the difference  
151 between the core and richness and it provides insight into transient microbiota. Changes in  
152 abundance of genera characterised as core microbiota at each sampling point are shown in  
153 **Figures 3** and **4**; interestingly, the core size was remarkably stable with an average of 34  
154 genera over the sampling period. It is noteworthy that *Mycobacterium*'s membership of the  
155 core was restricted to baseline samples before initiating therapy (**Figure 3**). The core  
156 comprised of genera like *Streptococcus*, *Veillonella*, *Neisseria*, *Fusobacterium*,

157 *Lachnoanaerobaculum*, *Atopobium*, *Peptostreptococcus* and *Leptotrichia*. Of these,  
158 *Streptococcus* was the most abundant but unlike *Veillonella*, its abundance was consistent  
159 before and after initiating therapy. Conversely, genera like *Neisseria* showed a steady  
160 increase over time. To track changes in the core, we identified 31 genera whose core  
161 membership was consistent across the three sampling points (**Figure 5**). The 31 genera are  
162 the same as genera characterised as normal flora; this core and normal flora as a proportion  
163 of sputum microbial richness was also stable across sampling points (**Figure 5**). In contrast,  
164 by month 2 after initiating treatment, the proportion of *Mycobacterium* dramatically fell while  
165 that of accessory microbiota fluctuated (**Figure 5**). It is worth noting that the proportion of  
166 accessory microbiota was at its highest at baseline and reduced at month 2 after initiating  
167 treatment.

168

169 Furthermore, in-depth investigation of the abundance of the microbiota components (core,  
170 accessory and oral-disease associated) showed subtle differences (**Figure 4**). At baseline,  
171 there were two groups of patients i.e. clusters ii & iii (**Fig 4, panel A**) with a comparatively  
172 depleted core but these patients had a relatively high bacillary load i.e. 100-200+ colony  
173 forming units (CFUs). Although not exclusive, clusters i & iv (**Fig 4, panel A**) were  
174 predominated by patients who had commenced treatment. We also examined signatures of  
175 change in genera associated with oral-disease and accessory microbiota (**Fig 4, panels B**  
176 and **C**); we observed clustering with varying levels of depletion of genera associated with  
177 oral-pathology, with cluster iv mapping to sampling points associated with treatment follow-  
178 up (**Fig 4, panel B**). This observation was not seen with accessory microbiota, suggesting  
179 that this microbial component is less discriminatory. We observed that the accessory  
180 component was most dominant at baseline with enrichments of genera like *Bergeyella*,  
181 *Lactobacillus*, *Actinobacillus* and *Johnsonella* in certain patient groups during treatment. At  
182 month 2 posttreatment commencement, the accessory size and composition was  
183 significantly depleted. To further investigate this change in biomass and families attributed,  
184 we used Quasi-Poisson model to identify 11 differentially abundant families at baseline i.e.



185 *Streptococcaceae*, *Neisseriaceae*, *Prevotellaceae* and *Peptostreptococcaceae*. These  
186 families also represent core membership described above and their differential abundance  
187 suggests dysbiosis at this point. Beyond month 2, the number of differentially abundant  
188 families reduced to seven. Furthermore, we noted that the abundance of core members  
189 significantly increased among patients with a high body mass index (BMI) compared to  
190 patients with low BMI by month 2 (**Figure 6**). We also noted that genera belonging to  
191 families *Tannerellaceae* and *Leptotrichiaceae* were exclusively differentially abundant after  
192 initiating therapy. Overall, this model shows that anti-TB therapy is associated with a  
193 reduction in microbial abundance/biomass with the largest change occurring at month 2  
194 posttreatment commencement.

195

#### 196 **Community co-occurrence patterns and variance**

197 Analysis of co-occurrence networks at baseline showed that the entire sputum microbiota  
198 community is linked by non-random relationships ( $p < 0.05$ ), **Fig.7 panel C** ('non-random  
199 relationships' refer to statistically significant patterns observed after applying a false  
200 discovery rate, FDR see Methods). Indeed, this was also seen at month 2 posttreatment  
201 commencement. Interestingly, at month 5 posttreatment commencement the proportion of  
202 random co-occurrence patterns was 70%. Co-occurrence network analysis of sputum  
203 samples at baseline revealed a community named x (**Fig.7 panel A**) predominated by  
204 genera belonging to accessory microbiota e.g. *Sulfitobacter*, *Pyramidobacter*, *Acidiphilium*,  
205 *Olivibacter* etc. By month 2, community x had shrunk in size but the co-occurrence network  
206 was still predominated by accessory microbiota. Indeed, there was a dramatic reduction in  
207 variance change (~4%) at month 2 posttreatment commencement attributed to 35 genera,  
208 none of which were similar to those observed at baseline although five (14%) of these  
209 belonged to the core microbiota (**Table S2**). The largest change in variance at baseline  
210 (15%) was attributed to 10 genera –*Roseomonas*, *Proteobacterium*, *Acidocella*, *Spirochaeta*,  
211 *Olivibacter*, *Stenotrophomonas*, *Blautia*, *Desulfobulbus*, *Parasegetibacter* and *Terrimonas*,  
212 all of which belonged to accessory microbiota (**Figure 7, panel B and Table S2**). In contrast,

213 at month 5 posttreatment commencement we observed up to 25% variance change  
214 attributed to 18 genera, 75% of which belonged to the core microbiota (**Figure 7 panel B**  
215 and **Table S2**).

216

217 Normal flora significantly contributes to maintenance of the integrity of several anatomical  
218 sites in the body. Core microbiota as characterised in this study is a close approximation of  
219 the normal flora of the oral cavity and lung<sup>11</sup>. Understanding how this microbiota component  
220 is affected by anti-TB drugs is central to how it can be leveraged to improve diagnostics and  
221 treatment response monitoring<sup>23</sup>. We have shown in this study that on average a TB patient  
222 had a core microbiota size of 34 genera at any given time, which remains stable during  
223 treatment. Although the core size did not change, the relative abundance of its constituents  
224 changed for example, a significantly low abundance of *Mycobacterium* at month 2 (which is  
225 expected as the administered drugs target this genus). Indeed at baseline before initiating  
226 treatment, *Mycobacterium* was a member of the core and it accounted for 1 in 500 bacteria  
227 in sputum. By months 2 and 5, the proportion of *Mycobacterium* fell to 1 in 5,000 and 1 in  
228 10,000 respectively, and its membership shifted to accessory microbiota. This observation,  
229 coupled with clustering of patients by Ziehl-Neelsen (ZN) sputum smear status, is in line with  
230 the importance of sputum as a sample of choice in TB diagnostics.

231

232 Furthermore, the observed change in abundance of the other members of the core  
233 microbiota i.e. genera like *Neisseria*, *Veillonella*, *Fusobacterium*, *Streptococcus*,  
234 *Actinobacteria*, *Capnocytophaga*, *Stomatobaculum* and *Prevotella* suggests dysbiosis<sup>11,16</sup>.  
235 Abnormality in microbiota composition and abundance (i.e. dysbiosis) is associated with  
236 dysregulation of the immune response, which alters the environment in favour of invading  
237 bacteria<sup>10</sup>. The observed high biomass of the accessory microbiota supports the notion that  
238 dysbiosis promotes proliferation of bad bacteria<sup>10</sup>. This accessory microbiota included  
239 genera like *Actinobacillus*, *Bergeyella* and *Fretibacterium*. On the other hand, genera  
240 constituting the core microbiota e.g. *Veillonella*, *Streptococcus*, *Peptostreptococcus*,

241 *Porphyromonas*, *Neisseria*, *Pasteurella* and *Prevotella* were highly abundant before initiating  
242 therapy and such differential abundance of members of the core has been observed  
243 before<sup>15,16</sup>. Within 2 months after initiating therapy, we noted a general reduction in total  
244 microbiota abundance. This may not be surprising because rifampicin, one of the first-line  
245 anti-TB drugs administered to patients, has broad-spectrum of activity<sup>11</sup> hence the  
246 overwhelming reduction in abundance of the microbiota. Even after controlling for factors like  
247 sex, HIV status and BMI, this marked change in abundance remained. This effect was more  
248 pronounced among genera that were abundant before initiating treatment, as well as  
249 *Tanerella*, *Leptotrichia*, *Lachnospira* and *Fusobacterium*, and it was also associated with a  
250 log reduction in abundance of the accessory microbiota.

251

252 In agreement with previous reports on effects of antibiotics on the microbiota<sup>24</sup>, we have  
253 shown that anti-TB treatment is associated with constriction in sputum microbiota community  
254 variance, lack of entropy and general reduction in biomass specifically that of accessory  
255 microbiota. The increase in community variance and entropy associated with 0.5 log  
256 increase in accessory microbiota at month 5 posttreatment commencement likely signals a  
257 gradual return to normal of the microbiota composition. We observed mainly positive rather  
258 than negative correlation, the latter being observed only at month 5 posttreatment  
259 commencement; this in addition to an increase in entropy could indeed signify sputum  
260 microbiota remodelling towards a normal/healthy state<sup>25</sup>. Overall, these findings suggest that  
261 accessory microbiota augments sputum microbiota dynamics but the pathobiological impact  
262 of this is currently unknown.

263

#### 264 **Clinical relevance of findings for TB endemic settings with high incidence of HIV**

265 As sputum is key in the diagnosis of pulmonary TB disease, investigation of sputum  
266 microbiota dynamics can inform efforts aiming to improve treatment response monitoring but  
267 this phenomenon is largely unexplored in Africa. In this study, sputum microbiota  
268 characteristics ably grouped patients as baseline (before initiating therapy) or treatment

269 follow-up (months 2 or 5) and certain microbiota attributes also mapped to common  
270 diagnostics like AFB smear staining. Therefore, there is potential for this analysis to inform  
271 minimum detection levels for common TB diagnostics. We propose a framework (see **Figure**  
272 **8**) for standardizing such methods for TB clinical metagenomics in the developing countries.  
273 The proposed framework combines a) sputum microbiota structure, b) taxonomic  
274 characteristics, and c) microbial network co-occurrence characteristics to provide holistic  
275 insight into microbial dynamics during therapy. This is critical because sputum only  
276 approximates the lung microbial distribution<sup>17</sup>, so relying on mere presence or absence of  
277 genera might be a misleading comparator.

278

## 279 **Conclusions**

280 Sputum microbiota of treatment-naïve TB patients has microbial signals associated with first-  
281 line anti-TB therapy. Overall, TB treatment with first-line drugs does not change the size but  
282 the abundance of the core microbiota. In contrast, the size, composition and abundance of  
283 the accessory microbiota to which *Mycobacterium* belongs changes significantly during  
284 treatment. Also, treatment constricts microbial community variance and entropy, which  
285 recovers at month 5 posttreatment commencement. Taken together, this demonstrates the  
286 potential utility of sputum microbiome to inform treatment response monitoring strategies  
287 and refining diagnostics in developing countries like Uganda.

288

## 289 **Methods**

### 290 **Study setting, patients and samples**

291 This longitudinal study was conducted at Mulago National Referral Hospital in Kampala,  
292 Uganda, between 2016 and 2018. Mulago is the largest public hospital in Uganda with 1,500  
293 beds, a TB clinic and a multidrug resistant (MDR)-TB treatment centre for the country.  
294 Around 5,000 TB patients are treated at the clinic every year, of whom one third are

295 previously treated patients<sup>26</sup>. We randomly enrolled 120 treatment-naïve TB patients 18  
296 years and older, collected sputum and profiled them before initiating anti-TB therapy which  
297 formed the baseline for the study. Pulmonary TB disease was clinically diagnosed by a  
298 Pulmonologist at the TB clinic and confirmed with the Xpert MTB/RIF test on sputum,  
299 sputum smear microscopy (by ZN staining for AFB) or LJ culturing at the BSL-3  
300 Mycobacteriology Laboratory, Makerere University College of Health Sciences. We collected  
301 additional sputum samples from the patients during treatment follow-up at months 2 and 5;  
302 we compared these to baseline samples to unravel the microbiota changes and dynamics  
303 after initiating therapy. To account for potential cofounders, we included a wide range of  
304 clinical and lifestyle variables. Sputum samples were collected with consent as part of  
305 routine clinical care however, to ensure consistency in quality and quantity of the sputum  
306 collected, sputum induction was performed by an expert Pulmonologist at the TB clinic as  
307 described previously<sup>27</sup>. Specimen containers with sputum were tightly closed and placed in  
308 plastic biohazard bags and immediately transported to the BSL-3 Mycobacteriology  
309 laboratory in ice-cool boxes for processing. Briefly, N-acetyl-l-cysteine-sodium hydroxide  
310 (NALC-NaOH) and RLT Plus lysis buffer (Qiagen) were added to the samples, vortexed and  
311 centrifuged at 3,000 g for 2 minutes to obtain pellets. Pellets were re-suspended in sterile  
312 phosphate buffered saline and aliquoted into 2 portions. One portion was used for ZN  
313 staining and culturing in the BACTEC-MGIT system and on LJ medium. Chromosomal DNA  
314 was extracted from the remaining portion of the pellet by using the AllPrep DNA/RNA Mini  
315 Kit (Qiagen).

316

### 317 **DNA sequencing and sequence analysis**

318 High throughput DNA sequencing targeting the V3-V4 region of the *16S rRNA* gene in  
319 sputum DNA was performed at the Integrated Microbiome Resource (IMR), Dalhousie  
320 University Canada (<https://imr.bio>)<sup>28,29</sup> on MiSeq platform (illumina Inc.). Sequence reads  
321 were processed by using the Quantitative Insights into Microbial Ecology version 2 software  
322 (QIIME-2)<sup>30</sup>. Briefly, raw paired-end sequence reads and metadata were combined to

323 generate a QIIME-2 object (artefact) for subsequent analysis<sup>30</sup>. Paired sequence reads were  
324 filtered for quality, dereplicated, chimeras removed and denoised by using DADA2<sup>30</sup>. This  
325 generated amplicon sequence variant (ASV) tables (previously known as operational  
326 taxonomic unit [OUT] tables) and representative sequences (in this study, the terms “ASVs”  
327 and “OTUs” are used interchangeably). The OTU tables were used to estimate alpha and  
328 beta diversity indices at an OTU minimum depth threshold of 2,000. This was followed by a  
329 step to identify potential contamination. Alpha diversity indices included observed OTUs and  
330 Shannon<sup>31</sup>. Beta diversity was estimated by using Bray-Curtis, weighted and unweighted  
331 uniFrac distances<sup>30</sup>. Phylogenetic analysis was inferred with phyloseq package v1.26.0<sup>32</sup>  
332 and Metacoder v0.3.2-based microbiome analysis in R statistical package (v3.5.1)<sup>14</sup> during  
333 beta diversity estimation. This was done by aligning the representative sequences, filtering  
334 out non-informative sites and generating a rooted tree using MAFFT and FASTTREE<sup>30</sup>  
335 software. The taxonomic classification of OTUs was achieved by using a naïve Bayes  
336 classifier trained on the most recent SILVA database at 97% similarity<sup>33</sup>. First, the training  
337 dataset was extracted by using primers used for sequencing the samples<sup>28</sup>, and the  
338 resultant dataset used to train the classifier for taxonomically assigning the OTUs.  
339 Visualisation of taxonomic abundance was done by using ggplot2 in R. Phylogenetic  
340 abundance shifts of microbiota were interrogated by using Metacoder v0.3.2<sup>32</sup>. Additional  
341 post-hoc statistical analysis was done in R using phyloseq package v1.26.0<sup>31</sup>.

342

### 343 **Microbiota community structure and clinical covariates**

344 To assess the explanatory power/effect size of variables for changes in community structure,  
345 we used sampling time at months 2 and 5 as proxy for monitoring anti-TB treatment. We  
346 performed a constrained analysis of distance-based redundancy; in this case we used Bray-  
347 Curtis as the outcome variable and sampling point and ZN sputum smear staining as the  
348 explanatory variables. To estimate the cumulative effect size of all our explanatory variables,  
349 we used PERMANOVA models with adonis function (9,999 permutations) in phyloseq

350 v1.26.0<sup>32</sup> to identify microbiota structure-associations. In addition, we compared Shannon  
351 diversity index and Richness using ANOVA and Kruskal Wallis depending on normality<sup>31</sup>.

352

### 353 **Characterising core and accessory microbiota**

354 To determine the core and accessory microbiota, we used the microbiome package in R  
355 <https://github.com/microbiome/microbiome>. To track changes in the core as proportion of  
356 richness across sampling points, we used genera that were common to all cores for the  
357 three sampling points i.e. baseline, months 2 and 5.

358

### 359 **Co-occurrence networks analysis**

360 To identify genera that co-occur at each sampling point, we used pairwise correlation  
361 method in the microbiome package v1.4.2 in R. First, we generated a genus-level spearman  
362 correlation matrix with mean abundances. Note that we applied a false discovery rate (FDR,  
363 Benjamini–Hochberg–Yekutieli) and filtered the adjusted p-value at 0.005 to limit spurious  
364 associations<sup>34</sup>. We then pruned the matrix using correlation coefficient ( $\rho$ )  $\leq 0.7$  and  $\geq -0.4$ .  
365 The resultant matrix was converted into a directed-network object from which communities  
366 were extracted and visualised in igraph package v1.2. To investigate changes in entropy i.e.  
367 if the co-occurrence patterns observed were non-random (non-random are the statistically  
368 significant patterns after applying FDR), we tracked the proportion of Random and Non-  
369 random patterns before and during therapy.

370

### 371 **Impact on total variance**

372 To identify the influential genera (individual or groups of genera), we performed principal  
373 coordinate analysis (PCoA) and quantified total variance. Here total variance was the sum of  
374 variance explained by components 1-5 in a PCoA. Then, we sequentially removed the top  
375 50 genera ranked by their network centrality (betweenness degree) in the co-occurrence  
376 network to compute the change in variance. The change in variance and attributable genera  
377 were plotted as a bar plot in ggplot2 coloured by oxygen utilisation (aerobic, anaerobic, etc.).

378 The oxygen utilisation in this case was used as a functional community identifier based on  
379 the genera's biological process Go-term in UniProt <https://www.uniprot.org>

380

### 381 **Poisson regression model for biomass**

382 To assess changes in biomass and identify the associated clinical and lifestyle factors, we  
383 developed a Poisson regression model in glm using lme4 package in R. Here we assessed  
384 abundance at family level to minimise the number of covariate patterns. The families  
385 selected corresponded to core membership across the study period to ensure equal  
386 representation across the sampling points. Since the biomass variance was vastly different  
387 from the mean abundance, we used the quasi Poisson model. Here we developed a model  
388 with the same explanatory variables for each of the three sampling points and compared  
389 model estimates to determine the impact of TB therapy on sputum biomass.

390

### 391 **Ethical approval and consent to participate**

392 Ethical approval was provided by the Research and Ethics Committee of the School of  
393 Biomedical Sciences, Makerere University College of Health Sciences (reference #s  
394 SBS381/SBS542). Written informed consent was obtained from all the participants prior to  
395 enrolment into the study. All study methods were performed in accordance with the relevant  
396 guidelines and regulations.

397

## 398 **References**

- 399 1 Organization, W. H. & Organization, W. H. The top 10 causes of death. 2014. *Fact*  
400 *sheet* (2018).
- 401 2 Organization, W. H. Global tuberculosis report 2016. 2016. *Google Scholar*, 214  
402 (2018).
- 403 3 Tuberculosis, U. N. & Programme, L. C. (2017).
- 404 4 Theron, G. *et al.* Feasibility, accuracy, and clinical effect of point-of-care Xpert  
405 MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre,  
406 randomised, controlled trial. *The Lancet* **383**, 424-435 (2014).
- 407 5 Wipperman, M. F. *et al.* Antibiotic treatment for Tuberculosis induces a profound  
408 dysbiosis of the microbiome that persists long after therapy is completed. *Scientific*  
409 *reports* **7**, 1-11 (2017).



- 410 6 WHO. (World Health Organization Geneva, 2017).
- 411 7 Rockwood, N., du Bruyn, E., Morris, T. & Wilkinson, R. J. Assessment of treatment  
412 response in tuberculosis. *Expert Rev Respir Med* **10**, 643-654,  
413 doi:10.1586/17476348.2016.1166960 (2016).
- 414 8 Ambreen, A., Jamil, M., Rahman, M. A. u. & Mustafa, T. Viable Mycobacterium  
415 tuberculosis in sputum after pulmonary tuberculosis cure. *BMC Infectious Diseases*  
416 **19**, 923, doi:10.1186/s12879-019-4561-7 (2019).
- 417 9 Su, W.-J., Feng, J.-Y., Chiu, Y.-C., Huang, S.-F. & Lee, Y.-C. Role of 2-month sputum  
418 smears in predicting culture conversion in pulmonary tuberculosis. *European*  
419 *Respiratory Journal* **37**, 376-383, doi:10.1183/09031936.00007410 (2011).
- 420 10 Consortium, I. H. i. R. N. The integrative human microbiome project. *Nature* **569**,  
421 641-648 (2019).
- 422 11 Hong, B.-Y. *et al.* Microbiome changes during tuberculosis and antituberculous  
423 therapy. *Clinical microbiology reviews* **29**, 915-926 (2016).
- 424 12 Namasivayam, S., Sher, A., Glickman, M. S. & Wiperman, M. F. The microbiome and  
425 tuberculosis: early evidence for cross talk. *MBio* **9**, e01420-01418 (2018).
- 426 13 Pechal, J. L., Schmidt, C. J., Jordan, H. R. & Benbow, M. E. A large-scale survey of the  
427 postmortem human microbiome, and its potential to provide insight into the living  
428 health condition. *Scientific reports* **8**, 1-15 (2018).
- 429 14 Handelsman, J., Rondon, M. R., Brady, S. F., Clardy, J. & Goodman, R. M. Molecular  
430 biological access to the chemistry of unknown soil microbes: a new frontier for  
431 natural products. *Chemistry & biology* **5**, R245-R249 (1998).
- 432 15 Cheung, M. K. *et al.* Sputum microbiota in tuberculosis as revealed by 16S rRNA  
433 pyrosequencing. *PLoS One* **8** (2013).
- 434 16 Krishna, P., Jain, A. & Bisen, P. Microbiome diversity in the sputum of patients with  
435 pulmonary tuberculosis. *European Journal of Clinical Microbiology & Infectious*  
436 *Diseases* **35**, 1205-1210 (2016).
- 437 17 Garcia, B. J. *et al.* Sputum is a surrogate for bronchoalveolar lavage for monitoring  
438 Mycobacterium tuberculosis transcriptional profiles in TB patients. *Tuberculosis* **100**,  
439 89-94 (2016).
- 440 18 Botero, L. E. *et al.* Respiratory tract clinical sample selection for microbiota analysis  
441 in patients with pulmonary tuberculosis. *Microbiome* **2**, 29 (2014).
- 442 19 Luo, M. *et al.* Alternation of gut microbiota in patients with pulmonary tuberculosis.  
443 *Frontiers in physiology* **8**, 822 (2017).
- 444 20 Wu, J. *et al.* Sputum microbiota associated with new, recurrent and treatment failure  
445 tuberculosis. *PloS one* **8** (2013).
- 446 21 Falony, G. *et al.* Population-level analysis of gut microbiome variation. *Science* **352**,  
447 560-564 (2016).
- 448 22 Astudillo-García, C. *et al.* Evaluating the core microbiota in complex communities: a  
449 systematic investigation. *Environmental microbiology* **19**, 1450-1462 (2017).
- 450 23 Garcia, C. *et al.* High frequency of diarrheagenic Escherichia coli in human  
451 immunodeficiency virus (HIV) patients with and without diarrhea in Lima, Peru. *Am J*  
452 *Trop Med Hyg* **82**, 1118-1120, doi:10.4269/ajtmh.2010.09-0460 (2010).
- 453 24 Langdon, A., Crook, N. & Dantas, G. The effects of antibiotics on the microbiome  
454 throughout development and alternative approaches for therapeutic modulation.  
455 *Genome medicine* **8**, 39 (2016).

- 456 25 Mainali, K., Bewick, S., Vecchio-Pagan, B., Karig, D. & Fagan, W. F. Detecting  
457 interaction networks in the human microbiome with conditional Granger causality.  
458 *PLoS computational biology* **15**, e1007037 (2019).
- 459 26 Bwanga, F., Haile, M., Joloba, M. L., Ochom, E. & Hoffner, S. Direct nitrate reductase  
460 assay versus microscopic observation drug susceptibility test for rapid detection of  
461 MDR-TB in Uganda. *PLoS One* **6** (2011).
- 462 27 Bell, D., Leckie, V. & McKendrick, M. The role of induced sputum in the diagnosis of  
463 pulmonary tuberculosis. *Journal of Infection* **47**, 317-321 (2003).
- 464 28 Comeau, A. M., Douglas, G. M. & Langille, M. G. Microbiome helper: a custom and  
465 streamlined workflow for microbiome research. *MSystems* **2** (2017).
- 466 29 Walters, W. *et al.* Improved bacterial 16S rRNA gene (V4 and V4-5) and fungal  
467 internal transcribed spacer marker gene primers for microbial community surveys.  
468 *Msystems* **1**, e00009-00015 (2016).
- 469 30 Bolyen, E. *et al.* QIIME 2: Reproducible, interactive, scalable, and extensible  
470 microbiome data science. Report No. 2167-9843, (PeerJ Preprints, 2018).
- 471 31 McMurdie, P. J. & Holmes, S. phyloseq: an R package for reproducible interactive  
472 analysis and graphics of microbiome census data. *PloS one* **8** (2013).
- 473 32 Foster, Z. S., Sharpton, T. J. & Grünwald, N. J. Metacoder: an R package for  
474 visualization and manipulation of community taxonomic diversity data. *PLoS*  
475 *computational biology* **13**, e1005404 (2017).
- 476 33 Quast, C. *et al.* The SILVA ribosomal RNA gene database project: improved data  
477 processing and web-based tools. *Nucleic acids research* **41**, D590-D596 (2012).
- 478 34 Proctor, L. M. *et al.* The Integrative Human Microbiome Project. *Nature* **569**, 641-  
479 648, doi:10.1038/s41586-019-1238-8 (2019).

480  
481

## 482 **Acknowledgements**

483 We thank: Professor Alison Elliott of Makerere University Infection & Immunity Programme  
484 (MUII-Plus) at the MRC/UVRI & LSHTM Uganda Research Unit, Entebbe, for useful  
485 comments on the manuscript; staff at the Mulago Hospital TB treatment centre and the BSL-  
486 3 Mycobacteriology laboratory at Makerere University for technical assistance; Harriet  
487 Nakayiza & Geraldine Nalwadda (Makerere University College of Health Sciences), and  
488 Joshua Mandre (MUII-plus, Entebbe) for administrative support.

489

490 This project is part of the EDCTP2 programme supported by the European Union (grant  
491 number TMA2018CDF-2357-MTI-Plus). The project was also supported in part by the  
492 DELTAS Africa Initiative (grant # 107743/Z/15/Z), the Africa Centre of Excellence in

493 Materials, Product Development & Nanotechnology (MAPRONANO) (Project ID Number:  
494 P151847, IDA Number: 5797-UG), and the Erasmus Mobility Grant. The DELTAS Africa  
495 Initiative is an independent funding scheme of the African Academy of Sciences (AAS),  
496 Alliance for Accelerating Excellence in Science in Africa (AESA), and supported by the New  
497 Partnership for Africa's Development Planning and Coordinating Agency (NEPAD Agency)  
498 with funding from the Wellcome Trust (Grant no. 107743) and the UK Government. The  
499 funders had no role in study design, data collection and analysis, decision to publish, or  
500 preparation of the manuscript.

501

## 502 **Author contributions statement**

503 DPK & AM conceived the study, analysed and interpreted the data and wrote the  
504 manuscript. SN & AO recruited study participants and collected sputum samples from the  
505 patients. MM, FN, EK, WS & FKA performed the molecular and microbiological procedures.  
506 DPK, LN, WS & MLJ supervised the study protocol. MM performed part of the bioinformatics  
507 analysis (under supervision of DPK, AM & LN) in partial fulfilment of the requirements for the  
508 award of the degree of Master of Science in Immunology & Clinical Microbiology of  
509 Makerere University. All authors read and approved the final manuscript.

510

## 511 **Additional information**

### 512 **Competing interests**

513 The authors declare no competing interests

514

### 515 **Data Availability**

516 All data generated or analyzed during this study are included in this published article (and its  
517 Supplementary Information files). The raw sequence data was deposited with links to

518 BioProject accession number PRJNA564562 in the NCBI BioProject database

519 <https://www.ncbi.nlm.nih.gov/bioproject/>

520

## 521 **Figure legends**

522 **Figure 1: Study design and layout in this study.** Dark red, orange and green icons depict  
523 Baseline (before initiating therapy), Months 2 and 5 posttreatment commencement,  
524 respectively. A total of 120 pulmonary TB patients were enrolled at baseline but on follow-  
525 up, we screened 44 and 41, respectively.

526

527 **Figure 2: Microbial diversity analysis during first-line anti-TB treatment.** Panel A shows  
528 Alpha diversity analysis for indices like Richness, Simpson and Shannon. Panel B shows  
529 Beta diversity analysis based on constrained ordination of the Bray-Curtis distances. The  
530 green and colors represent positive and negative outcomes on routine smear diagnosis. B-  
531 line, Baseline before initiating therapy; Fist-FLUP, First follow up (month 2); Second FLUP,  
532 Second follow up (month 5).

533

534 **Figure 3: Taxonomic characteristics of the microbiota during anti-TB therapy. Panel 3**  
535 depicts composition of the core genera during treatment as defined by the QIIME-2  
536 microbiome package. Note that the genus *Mycobacterium* is a member of the core before  
537 initiating therapy but not during/after treatment.

538

539 **Figure 4: Changes in composition and abundance of the core microbiota (panel A),**  
540 **normal flora (panel B) and accessory microbiota during treatment (panel C).** The  
541 clustering i-v shows patient groupings some of which correspond to clinical diagnostics like  
542 sputum smear microscopy results, bacillary load (CFU), HIV status and body mass index  
543 (BMI).

544

545 **Figure 5: Changes in proportion of richness attributed to the core microbiota,**  
546 **accessory microbiota, oral-disease associated microbiota and *Mycobacterium*.**

547

548 **Figure 6: Changes in biomass using Poisson regression model.** Blue, green and orange  
549 colors depict estimates of biomass at Baseline, month 2 (first visit) and month 5 (second  
550 visit) after initiating therapy. The pseudo R<sup>2</sup> = 0.67, 0.95, and 0.94 for models, respectively.  
551 \*\*\*p <0.001; \*\*p<0.01; \*p<0.05.

552


553 **Figure 7: Shows changes in co-occurrence network patterns, variance and entropy.**


554 **Panel A** depicts remodeling of co-occurrence network during treatment. We highlight a  
555 community 'x' whose membership appears to change 2 months after initiating therapy.

556 **Panel B** depicts change in variance attributed to genera with the highest centrality degree in  
557 co-occurrence network. Color coding represents oxygen utilization. **Panel C** depicts changes  
558 in proportion pairwise co-relations that are statistically significant. This was used as a  
559 measure of entropy i.e. 100% statistically significant (non-random) and random representing  
560 lack of entropy and high entropy, respectively. B-line, Baseline before initiating therapy;  
561 First-FLUP, First follow up (month 2); Second FLUP, Second follow up (month 5).


562

563 **Figure 8: Proposed framework for characterizing sputum microbiota during anti-TB**  
564 **therapy in TB endemic settings with high rates of HIV infection.** This model emphasizes  
565 use of microbiota structure, taxonomic characteristics, and co-occurrence networks including  
566 its variance and entropy.






Sampling.point  B-line  First-FLUP  Second-FLUP




Smear\_Test  Negative  Positive

Sampling.point  B-line  First-FLUP  Second-FLUP


Sputum core microbiota at baseline




Sputum core microbiota at First followup






Sputum core microbiota at Second followup




Prevalence







**A****B****C**





**A****B**

Oxygen\_use

<span style="color: red;">■</span> Aerobic	<span style="color: green;">■</span> Facultative_aerobic	<span style="color: orange;">■</span> Microaerophilic	<span style="color: brown;">■</span> Obligate_Anaerobic
<span style="color: blue;">■</span> Anaerobic	<span style="color: purple;">■</span> Facultative_anaerobes	<span style="color: yellow;">■</span> Obligate_Aerobic	<span style="color: pink;">■</span> Unknown

**C**